K2F&B(02108.HK)上半年純利升33.16%至131.3萬坡元
格隆匯8月24日丨K2F&B(02108.HK)公佈中期業績,截至2021年6月30日止6個月,公司收入為1859.1萬坡元,同比增長14.70%;期內溢利為131.3萬坡元,同比增長33.16%;每股盈利為0.16坡元。
於報吿期內及2020年上半年,銷售熟食、飲品及煙草產品為集團的最大收益來源,分別佔集團的收益的約78.0%及80.4%。銷售熟食、飲品及煙草產品所產生的收益由約1300萬新加坡元增加約150萬新加坡元或11.3%至約1450萬新加坡元。增加主要由於報吿期堂食限制放寬,客户適應新常態,而於2020年上半年阻斷措施期間則未能堂食,非必要工作場所亦關閉。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.